Sequential immune monitoring in patients with melanoma and renal cell carcinoma treated with high-dose interleukin-2: immune patterns and correlation with outcome.

The article discusses a study of metastatic melanoma (MMEL) and metastatic renal cell carcinoma (MRCC) patients undergoing Interleukin -2 (IL-2) therapy to determine the correlation between T cell subset distribution and IL-2 therapy success. Topics include the use of flow cytometry to evaluate patient immune profiles, the comparison of changes in the distribution and phenotype of circulating CD4 and CD8 lymphocyte subsets, and treatment impact on effector lymphocytes and T cells.